Specific Diagnostics, Inc.
West Palm Beach, FL · CIK 0001802480 · Medtech · Acquired
Rapid antimicrobial susceptibility testing (AST) system using proprietary volatile-sensing sensor arrays to deliver phenotypic susceptibility results from blood cultures in ~5 hours
specificdx.com →- Grants
- $11M
- 9 awards
- Sector median: 1
- Raised
- $17M
- 1 Form D · Feb 2020
- 80 months since last filing
- Contracts
- $249K
- 1 award · Defense
- #438 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Combining faster detection with ID: a new paradigm for mycobacterial culture | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing. | $998,141 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Combining faster detection with ID: a new paradigm for mycobacterial culture | $1,000,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing. | $995,444 | |
| Federal grant | Department of Health and Human Services · Phase II · Combining faster detection with ID: a new paradigm for mycobacterial culture | $983,752 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing. | $996,128 | |
| Private capital raised | Form D · SEC | $17,499,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing | $2,974,026 | |
| Federal contract | Department of Defense · Medical Research And Development Dha SBIR Ph I Dha 202-001-0033 Titled Rapid Bacterlophage Susceptibility Testing Using Small Molecule Sensor Technology | $248,845 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing | $977,172 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing | $998,154 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 435 | Terapio Corp | $250K | $574K |
| 436 | TYMPANOGEN, INC. | $250K | $2.2M |
| 437 | Akrotome Imaging, INC | $250K | — |
| 438 | Specific Diagnostics, Inc. | $249K | $17M |
| 439 | Otolith Sound Inc | $248K | $31M |
| 440 | INSTADIAGNOSTICS INC | $244K | — |
| 441 | InnoTech Precision Medicine, Inc | $244K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Paul GrossmanDirector
- Ray MartinoDirector
- Paul RhodesDirector · Executive Officer
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.